Leadership

Eric Lindquist is a proven pharmaceutical and diagnostics executive and board member with decades of leadership experience. Most recently, he served as CEO of InnoSIGN, a U.S.- and Netherlands-based techbio company, where he led a strategic pivot and completed two financing rounds.

Prior to InnoSIGN, he was Chief Business and Commercial Officer at Celcuity, where he led the acquisition of gedatolisib and helped advance the program into Phase III breast cancer trials, which have reported highly positive outcomes for patients. Earlier in his career, he held senior leadership roles at Natera (NASDAQ: NTRA), where he helped launch Signatera, a personalized diagnostic built around each patient’s unique cancer signature, and previously helped establish Roche as a leader in companion diagnostics.

He earned a B.S. from the University of Minnesota and an MBA from Capella University.